We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+1.18%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$704K
(+0.28%)
Cap. Flow
+$4.85M
Cap. Flow
% of AUM
1.91%
Top 10 Holdings %
Top 10 Hldgs %
43.68%
Holding
90
New
20
Increased
18
Reduced
11
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$9.28M |
| 2 |
Takeda Pharmaceutical
TAK
|
+$9.02M |
| 3 |
SIEN
Sientra, Inc.
SIEN
|
+$8.62M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$8.05M |
| 5 |
Humana
HUM
|
+$7.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$13.8M |
| 2 |
Gilead Sciences
GILD
|
+$10.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$9.55M |
| 4 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$5.99M |
| 5 |
Evolent Health
EVH
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.04% |
| 2 | Technology | 6.14% |
| 3 | Industrials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Bristol-Myers Squibb
BMY
$133B
| $3.91M | 1.54% |
86,297
-204,984
| -70% | -$9.55M |
|
27
Liquidia Corp
LQDA
$7.48B
| $3.75M | 1.48% |
468,981
+233,652
| +99% | +$2.19M |
|
28
Aclaris Therapeutics
ACRS
$726M
| $3.57M | 1.41% |
1,629,327
+1,083,598
| +199% | +$5.91M |
|
|
GWPH
29
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.14M | 1.24% |
+18,210
| New | +$3.15M |
|
30
Integra LifeSciences
IART
$1.29B
| $2.39M | 0.94% |
+42,827
| New | +$2.21M |
|
31
Surgery Partners
SGRY
$2.01B
| $2.34M | 0.92% |
287,720
+248,915
| +641% | +$2.48M |
|
|
NTGN
32
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $2.21M | 0.87% |
465,650
+40,359
| +9% | +$226K |
|
|
RVLP
33
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $1.95M | 0.77% |
514,239
+234,678
| +84% | +$780K |
|
34
DaVita
DVA
$15.4B
| $1.83M | 0.72% |
+32,566
| New | +$1.69M |
|
|
GRTS
35
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.6M | 0.63% |
143,752
+122,495
| +576% | +$1.4M |
|
|
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.5M | 0.59% |
90,547
-18,778
| -17% | -$326K |
|
37
SI-BONE Inc
SIBN
$788M
| $1.33M | 0.52% |
+65,216
| New | +$1.12M |
|
38
Tandem Diabetes Care
TNDM
$1.34B
| $1.26M | 0.5% |
+19,579
| New | +$1.26M |
|
39
Bio-Rad Laboratories Class A
BIO
$8.71B
| $1.17M | 0.46% |
+3,735
| New | +$1.12M |
|
|
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
| $1.14M | 0.45% |
+289,714
| New | +$1.51M |
|
41
Pediatrix Medical
MD
$2.18B
| $994K | 0.39% |
+39,401
| New | +$1.06M |
|
42
Actinium Pharmaceuticals
ATNM
$26.3M
| $610K | 0.24% |
+82,712
| New | +$831K |
|
43
Sarepta Therapeutics
SRPT
$1.57B
| $570K | 0.22% |
3,753
-10,611
| -74% | -$1.29M |
|
44
Align Technology
ALGN
$12.1B
| $537K | 0.21% |
1,962
-4,595
| -70% | -$1.39M |
|
|
CBIO
45
Crescent Biopharma
CBIO
$537M
| $504K | 0.2% |
+423
| New | +$506K |
|
|
TBIO
46
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $490K | 0.19% |
+38,772
| New | +$409K |
|
|
ADVM
47
DELISTED
Adverum Biotechnologies
ADVM
| $379K | 0.15% |
+3,187
| New | +$264K |
|
48
Agilent Technologies
A
$39.1B
| – | – |
-12,583
| Closed | -$1.01M |
|
49
Abbott
ABT
$183B
| – | – |
-23,966
| Closed | -$1.92M |
|
50
Aldeyra Therapeutics
ALDX
$92.9M
| – | – |
-23,576
| Closed | -$213K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Endurant Capital Management held 90 positions worth $254M, up 0.28% from $253M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management's Q2 2019 filing shows 20 new, 18 increased, 11 reduced and 40 closed positions. Its largest new stake was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M. The largest sale was Icon, an estimated $13.8M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Technology and Industrials.
- Endurant Capital Management's largest Q2 2019 buy was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
- Endurant Capital Management added most to Takeda Pharmaceutical in Q2 2019, an estimated $9.02M increase.
- Endurant Capital Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $9.55M.
- Endurant Capital Management fully exited Icon in Q2 2019, selling an estimated $13.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $254M portfolio in Q2 2019.
- Endurant Capital Management opened 20 new positions and closed 40 in Q2 2019.
- Endurant Capital Management's portfolio value rose 0.28% quarter-over-quarter to $254M.
Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.